RELATIVE VARIABILITY OF PROGRAF, NEORAL & CELLCEPT IN DIABETIC KIDNEY TXT PTS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。糖尿病患者通常患有被称为胃轻瘫的消化问题。这些消化问题会干扰你的抗排斥药物的吸收。这些抗排斥药物吸收不良会导致移植肾发生排斥反应的风险更高。糖尿病移植患者对许多抗排斥药物的吸收情况尚不完全了解，这些药物包括尼罗拉、普罗格拉夫和赛诺普。这项临床研究的目的是确定一种更能被糖尿病移植患者吸收的抗排斥药物方案。在这项研究中，受试者从Neole切换到Prograf，并将继续服用泼尼松和Cellcept。受试者还要每月抽血6次，每次12小时。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Diabetic patients typically suffer from digestive problems referred to as gastroparesis. These digestive problems can interfere with absorption of your anti-rejection medication. Poor absorption of these anti-rejection medications can lead to a higher risk of rejection of the transplanted kidney. The absorption of many anti-rejection drugs, namely Neoral, Prograf, and Cellcept, is not fully understood in diabetic transplant patients. The purpose of this clinical research study is to identify an anti-rejection medication regimen that is better absorbed by transplant patients with diabetes. In this study, subjects are switched from Neoral to Prograf and will continue to remain on prednisone and Cellcept. Subjects also undergo 6 monthly 12-hour blood draw profiles.